-
公开(公告)号:US20140221398A1
公开(公告)日:2014-08-07
申请号:US14117927
申请日:2012-05-16
IPC分类号: C07D487/04
CPC分类号: C07D487/04
摘要: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
摘要翻译: 本公开提供了酪氨酸激酶抑制剂,特别是BLK,BMX,EGFR,HER2,HER4,ITK,Jak3,TEC,Btk和TXK的化合物和药学上可接受的盐,因此可用于治疗可通过抑制 酪氨酸激酶如癌症和炎性疾病如关节炎等。 还提供了含有这些化合物的药物组合物和药学上可接受的盐以及制备这些化合物和药学上可接受的盐的方法。
-
公开(公告)号:US09376438B2
公开(公告)日:2016-06-28
申请号:US14117927
申请日:2012-05-16
IPC分类号: C07D487/04 , A61K31/519 , A61P35/00 , A61P35/02 , A61P35/04 , A61P29/00 , A61P19/02 , A61P11/06 , A61P17/06
CPC分类号: C07D487/04
摘要: The present disclosure provides compounds of Formula (I)and pharmaceutically acceptable salts that are tyrosine kinase inhibitors,in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
摘要翻译: 本公开提供式(I)化合物和其药学上可接受的盐,其是酪氨酸激酶抑制剂,特别是BLK,BMX,EGFR,HER2,HER4,ITK,Jak3,TEC,Btk和TXK,因此可用于治疗 通过抑制酪氨酸激酶如癌症和炎性疾病如关节炎等可治疗的疾病。 还提供了含有这些化合物的药物组合物和药学上可接受的盐以及制备这些化合物和药学上可接受的盐的方法。
-
公开(公告)号:US20140094459A1
公开(公告)日:2014-04-03
申请号:US14117933
申请日:2012-05-16
IPC分类号: C07D487/04 , A61K45/06 , A61K31/5377 , A61K31/519
CPC分类号: C07D487/04 , A61K31/519 , A61K31/5377 , A61K45/06
摘要: The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.
摘要翻译: 本公开提供了酪氨酸激酶抑制剂,特别是BLK,BMX,EGFR,HER2,HER4,ITK,TEC,BTK和TXK的化合物及其药学上可接受的盐,因此可用于治疗通过抑制酪氨酸可治疗的疾病 激酶如癌症和炎性疾病如关节炎等。 还提供含有这些化合物及其药学上可接受的盐的药物组合物和制备这些化合物的方法及其药学上可接受的盐。
-
公开(公告)号:US09187487B2
公开(公告)日:2015-11-17
申请号:US14117885
申请日:2012-05-16
IPC分类号: C07D487/04 , A61K45/06 , A61K31/4985 , A61K31/5377
CPC分类号: C07D487/04 , A61K31/4985 , A61K31/5377 , A61K45/06
摘要: The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.
摘要翻译: 本公开提供了酪氨酸激酶抑制剂,特别是BLK,BMX,EGFR,HER2,HER4,ITK,JAK3,TEC,Btk和TXK的化合物和药学上可接受的盐,因此可用于治疗可通过抑制 酪氨酸激酶如癌症和炎性疾病如关节炎等。 还提供了含有这些化合物的药物组合物和药学上可接受的盐以及制备这些化合物和药学上可接受的盐的方法。
-
公开(公告)号:US20100021423A1
公开(公告)日:2010-01-28
申请号:US12460658
申请日:2009-07-22
申请人: Kenneth Albert Brameld , David Scott Carter , Elbert Chin , Javier de Vicente Fidalgo , Jim Li , Ryan Craig Schoenfeld , Eric Brian Sjogren , Francisco Xavier Talamas
发明人: Kenneth Albert Brameld , David Scott Carter , Elbert Chin , Javier de Vicente Fidalgo , Jim Li , Ryan Craig Schoenfeld , Eric Brian Sjogren , Francisco Xavier Talamas
IPC分类号: A61K38/20 , A61K38/21 , C12N5/02 , A61K38/17 , A61K31/4412 , C07D213/63
CPC分类号: C07D213/64 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/10 , C07D413/10
摘要: Compounds having the formula I wherein R1, R2, R3, R4a, R4b, R4c, R5, R6, R9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
摘要翻译: 具有式I的化合物,其中R1,R2,R3,R4a,R4b,R4c,R5,R6,R9和n如本文所定义,是丙型肝炎病毒NS5b聚合酶抑制剂。 还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
-
公开(公告)号:US08273773B2
公开(公告)日:2012-09-25
申请号:US12460658
申请日:2009-07-22
申请人: Kenneth Albert Brameld , David Scott Carter , Elbert Chin , Javier de Vicente Fidalgo , Jim Li , Ryan Craig Schoenfeld , Eric Brian Sjogren , Francisco Xavier Talamas
发明人: Kenneth Albert Brameld , David Scott Carter , Elbert Chin , Javier de Vicente Fidalgo , Jim Li , Ryan Craig Schoenfeld , Eric Brian Sjogren , Francisco Xavier Talamas
IPC分类号: A61K31/4412 , C07D213/64
CPC分类号: C07D213/64 , C07D401/10 , C07D401/12 , C07D405/04 , C07D405/10 , C07D409/10 , C07D413/10
摘要: Compounds having the formula I wherein R1, R2, R3, R4a, R4b, R4c, R5, R6, R9 and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
摘要翻译: 具有式I的化合物,其中R1,R2,R3,R4a,R4b,R4c,R5,R6,R9和n如本文所定义,是丙型肝炎病毒NS5b聚合酶抑制剂。 还公开了用于治疗HCV感染和抑制HCV复制的组合物和方法。
-
-
-
-
-